<DOC>
	<DOCNO>NCT02845908</DOCNO>
	<brief_summary>The aim study compare efficacy safety FOLFOX , POF FOLFOX plus paclitaxel ( ip ) first-line treatment AGC phase II clinical trial .</brief_summary>
	<brief_title>POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel AGC</brief_title>
	<detailed_description>The biweekly 5-fluorouracil leucovorin ( LV5FU2 ) regimen associate oxaliplatin ( FOLFOX ) active patient AGC . Meanwhile , Paclitaxel monotherapy also active patient AGC . In previous study , find POF ( A combination oxaliplatin , fluorouracil Paclitaxel ) regimen appear good efficacy well tolerated patient advance gastric cancer . This study do find three drug combination maintain manageable side effect well benefit two drug combination . Intraperitoneal paclitaxel show high local concentration abdominal cavity low systemic toxicity . This study do find combination Intraperitoneal paclitaxel FOLFOX high local control rate lower systemic toxicity .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>ECOGPS 01 Age : 7075 year old ; ECOGPS 02 Age : 1870 year old ; Patients must histologically cytologically confirm metastatic unresectable gastric gastroesophageal junction ( GEJ ) adenocarcinoma . GEJ adenocarcinoma may classify accord Siewert 's classification type I , II , III Histological documentation local recurrence metastasis strongly encourage , unless risk procedure outweigh potential benefit confirm metastatic disease . If histologic confirmation , metastases recurrence require documentation 2nd radiographic procedure ( eg . PET/CT scan MRI addition CT scan ) . If imaging procedure confirm recurrent metastatic disease , biopsy confirmation require . Patients must disease evaluate radiographically . This may measurable disease nonmeasurable disease . Measurable disease define measure least one dimension &gt; 20 mm conventional technique , &gt; 10 mm high resolution image . Disease identify radiology study , meet criterion measurable disease , consider nonmeasurable . Patients may receive prior chemotherapy metastatic unresectable disease . Patients may receive prior adjuvant therapy ( chemotherapy and/or chemoradiation ) 6 month elapse end adjuvant therapy registration . Patients may receive prior oxaliplatin , fluorouracil Paclitaxel . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 02 ; An expected survival ≥ 3 month ; Major organ function meet follow criterion ; ( 1 ) For result blood routine test : Hemoglobin ( HB ) ≥ 80g / L , ANC ( absolute neutrophil count ) ≥ 1.5 × 109 / L , PLT ( blood platelet ) ≥ 75 × 109 / L , ( 2 ) For result biochemical test : BLT（total bilirubin） ≤ 1.25 time upper limit normal ( ULN ) , ALT ( Alanine aminotransferase ) AST ( aspartate aminotransferase ) ≤ 2.5 × ·ULN , liver metastasis , , ALT AST≤ 5 × ULN , Serum Cr（creatinine）≤1ULN , Endogenous creatinine clearance rate ＞50ml/min ; The patient PT（prothrombintime） ( INR international normalized ratio ) &lt; = 1.5 PTT（Partial Thromboplastin Time） &lt; = 3 second upper limit normal patientia anticoagulation . ·If patient fulldose anticoagulant , follow criterion meet enrollment : The patient must inrange INR ( usually 2 3 ) stable dose warfarin stable dose LMW ( Low molecular weight ) heparin The patient must active bleed pathological condition carry high risk bleeding ( e.g . tumor involve major vessel , know varix ) Pregnancy test ( serum urine ) perform woman childbearing age within 7 day enrolment test result must negative . Men woman childbearing potential must willing consent use effective contraception treatment least 3 month thereafter . Ability understand inform consent sign write informed consent document prior initiation protocol therapy . Patients receive previous chemotherapy treatment metastatic unresectable gastric GEJ adenocarcinoma ineligible . Patients receive previous pre postoperative chemotherapy chemoradiation ineligible therapy complete less 6 month prior study registration . Patients must recover adverse event previous therapy . Patients receive previous oxaliplatin , fluorouracil Paclitaxel . Patients history another neoplastic disease within past three year , exclude basal cell carcinoma skin , cervical carcinoma situ , nonmetastatic prostate cancer . Patients brain central nervous system metastasis , include leptomeningeal disease . Pregnant ( positive pregnancy test ) breast feeding . Serious , nonhealing wound , ulcer , bone fracture . Significant cardiac disease define : unstable angina , New York Heart Association ( NYHA ) grade II great , congestive heart failure , history myocardial infarction within 6 month Evidence bleed diathesis coagulopathy . History stroke CVA within 6 month Clinically significant peripheral vascular disease . Inability comply study and/or followup procedure . Patients medical condition reason , investigator 's opinion , make patient unstable participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>